Anti-Fibrinolytic Drugs - EU-27

EU-27

The revenue of the Anti-Fibrinolytic Drugs market in the EU-27 is estimated to reach US$2.26bn in 2024.
It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 4.45%, leading to a market volume of US$2.81bn by 2029.
Among all countries, United States is expected to generate the highest revenue with US$9,858.00m in 2024.
"The EU-27 market for anti-fibrinolytic drugs is experiencing a surge in demand due to the increasing prevalence of cardiovascular diseases in countries like Germany and France."

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Fibrinolytic Drugs are used to treat excessive bleeding by preventing the breakdown of blood clots. In the EU-27 region, the market for these drugs has been steadily growing in recent years.

Customer preferences: The preference for Anti-Fibrinolytic Drugs in the EU-27 region is driven by the high incidence of bleeding disorders, such as hemophilia, and the increasing use of these drugs in surgical procedures. Additionally, the aging population in the region has led to a higher demand for these drugs as the risk of bleeding increases with age.

Trends in the market: The market for Anti-Fibrinolytic Drugs in the EU-27 region is expected to continue growing due to the increasing prevalence of bleeding disorders and the rising number of surgical procedures. However, the market is also facing challenges such as the availability of alternative treatments and the high cost of these drugs.

Local special circumstances: In countries like Germany and France, where the healthcare system is highly regulated, the cost of Anti-Fibrinolytic Drugs is a major concern. As a result, the demand for generic versions of these drugs is increasing. In Eastern European countries, the market for Anti-Fibrinolytic Drugs is still in its nascent stage due to the low awareness of bleeding disorders and limited access to healthcare facilities.

Underlying macroeconomic factors: The growing demand for Anti-Fibrinolytic Drugs in the EU-27 region is also influenced by macroeconomic factors such as the increasing healthcare expenditure and the growing pharmaceutical industry. The region has a well-established healthcare infrastructure and the government's focus on improving healthcare services is expected to drive the growth of the Anti-Fibrinolytic Drugs market. Additionally, the presence of major pharmaceutical companies in the region is expected to boost the research and development of these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.